Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q3 2020 Earnings Conference Call - Final Transcript
Oct 15, 2020 • 08:00 am ET
Greetings and welcome to the BrainStorm Cell Therapeutics' Third Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is recorded.
And I would now like to introduce your host for today's conference, Michael Wood from LifeSci Advisors. Mr. Wood, you may begin.
Thank you everyone for joining the BrainStorm Cell Therapeutics earnings call. Before we begin the opening remarks, I would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative diseases such as ALS and MS, the sufficiency of the Company's existing capital resources for continuing operations in 2020 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the Company's ability to develop strategic collaborations and partnerships to support its business planning efforts.
Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond the Brainstorm's control, including the risks and uncertainties described from time-to-time in the Company's SEC filings. Results may differ materially from those projected on today's call. The Company undertakes no obligation to publicly update any forward-looking statements.
Joining us on the call today will be, Chaim Lebovits, President and CEO of BrainStorm; Dr. Ralph Kern, President and Chief Medical Officer; Dr. Stacy Lindborg, Executive VP and Head of Global Clinical Research; and Preetam Shah, Executive VP and CFO, they will be available to answer your questions during the Q&A session.
I would now like to turn the call over to Mr. Lebovits. Chaim, please go ahead.
Thanks, Michael. Welcome to Brainstorm's third quarter 2020 earnings call and thank you everyone for joining us. So far 2020 has been very productive for Brainstorm as we advance NurOwn in several neurological diseases, continue to build out our operating infrastructure capabilities and expanded our senior management team. We are focused on the upcoming topline readout for the NurOwn Phase III trial in ALS, which we expect to happen by the end of November.
We believe that a successful outcome for this trial will add a hope to the ALS community and will be a transformative moment for Brainstorm. Setting us on a path to filing a BLA and supporting our transition to a commercials to each company. The Phase III ALS trial is being conducted at six neurology centers of excellence in the United States.
I would like to once again thank all the investigators and their staff and the participating sites for the dedication, especially for enabling this trial to complete on time in the middle of an ongoing COVID-19 pandemic. I also want to express my complete gratitude to the trial participants and their loved ones for fully devoted themselves to the challenges of bringing in an investigational therapeutic forward.
Joining me on the call today are our President and Chief Medical Officer, Dr. Ralph Kern,